Abstract 19666: New Onset Atrial Fibrillation is Associated With Elevated Galectin-3 and Follistatin-Like 3 Levels
Background: Atrial fibrillation (AF) is a common cardiac arrhythmia, associated with increased risk of stroke and cardiac mortality. Atrial remodeling and atrial fibrosis have been suggested to participate in the pathogenesis of AF. Follistatin-like 3 (FSTL3) and Galectin-3 are secreted proteins that has regulatory roles in fibrosis, inflammation and tissue repair. Both have been reported to be associated with cardiac remodeling in heart failure. Furthermore, Galectin-3 levels have been shown to predict atrial remodeling and incidence of AF. Thus, in this study, we sought to examine whether differential FSTL3 and Galectin-3 levels predict chronicity of AF in patients.
Methods and Results: 134 patients hospitalized with AF were evaluated (mean age 69±12 yrs). Of those, 34 patients (26%) were diagnosed with new onset AF. Plasma Galectin-3 and follistatin-like 3 (FSTL3) levels were measured by commercially available ELISA assay. On univariate analyses, patients with new onset AF had i) significantly higher Galectin-3 levels vs those with chronic AF (mean 9.4ng/mL±3.3 vs. 8.0±3.5, p<0.05) and ii) tended to have higher FSTL3 levels (p<0.1). High Galectin-3 levels were also significantly correlated with NT-proBNP levels (R=0.3, p<0.01), CRP levels (R=0.3, p<0.01), and CHA2DS2VASc scores (R=0.2, p<0.05). On multivariate analysis, adjusting for age, gender, and creatinine, both high galectin-3 and FSTL3 levels remain independent correlates of presence of new onset AF (p<0.05 and p=0.006, respectively). Additionally, the combination of highest quartile of FSTL3 and Galectin-3 was further predictive of new onset AF (p<0.05) on multivariate analysis.
Conclusions: Recent onset of AF is associated with elevated galectin-3 and FSTL3 levels. This suggests that these could be used as new blood biomarkers of recent onset AF with the potential to predict atrial fibrosis and remodeling. The combination of Galectin-3 and FSTL3 may further enhance their diagnostic utility and form part of the multimarker strategy for assessment of AF.
Author Disclosures: D. Chen: None. N. Procter: None. S. Chua: None. V. Goh: None. S. Liu: None. B. Assadi-Khansari: None. J.D. Horowitz: None. D.T. Ngo: None. A.L. Sverdlov: None.
- © 2016 by American Heart Association, Inc.